Rich Heyman, Metacrine chairman (ARCH)

Metacrine, a Rich Hey­man biotech tar­get­ing NASH and oth­er liv­er dis­eases, rais­es $85M from IPO

A Rich Hey­man-backed start­up fo­cus­ing on NASH treat­ments, as well as oth­er liv­er, GI and meta­bol­ic dis­eases, is set to start trad­ing Wednes­day and join the al­ready-loaded class of 2020 biotech IPOs.

Metacrine has raised $85 mil­lion for its pub­lic of­fer­ing af­ter priced shares at $13 apiece, the mid­point of its ex­pect­ed range. Sell­ing 6.5 mil­lion shares, Metacrine makes good for a mar­ket val­ue of rough­ly $364 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.